Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CLODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CLODERM.
ARAZLO vs CLODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Cloderm (clocortolone pivalate) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins), which inhibit arachidonic acid release, reducing prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply a thin film to affected skin areas twice daily (morning and evening). Duration depends on severity and response.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is 72-120 hours (3-5 days) for clobetasol propionate, reflecting slow release from skin depot after topical application; systemic half-life after intravenous administration is approximately 2-3 hours.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; minimal unchanged drug excreted renally (<1%). Biliary/fecal excretion accounts for approximately 20% of total clearance.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid